As this article goes to press in late 2016, the precision medicine community has amassed over 20 years of companion product development experience in the field of oncology. This article reflects on what we have achieved and learned along the way, how the companion paradigm is playing out in immuno-oncology and why we are likely to achieve much more in the next 10 years than we have in the previous two decades. Also considered here are some of the disruptive operational and business model changes we will see in the coming years as these new opportunities are realized.
The current companion scenario has played out in targeted oncology since 1998, with the rate of innovation increasing in recent years. Indeed, over 45 new oncology drugs launched between 2010 and 2014 in more than 53 indications now extend life for many patients, while avoiding harm (toxicity) for others .
Click here to view the full article in Personalized Medicine.